Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | WDR5 | P61964 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 5/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.39 |
| ▸ | IDO1 | P14902 | 3/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | CTSA | P10619 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10303392 | 0.90 | FEN1 (0.45) | FEN1ALOX5APGRIN2BCYP11B1CYP11B2 | |
| SCHEMBL17359276 | 0.83 | FEN1 (0.41) | FEN1ALOX5APGRIN2B | |
| SCHEMBL10303256 | 0.83 | CNR2 (0.44) | CNR2WDR5FEN1ALOX5APIDO1 | |
| SCHEMBL10303374 | 0.82 | DHODH (0.47) | CNR2FEN1ALOX5APCYP11B1CYP11B2 | |
| SCHEMBL10303348 | 0.80 | PIM1 (0.42) | FEN1ALOX5APIDO1PGR | |
| SCHEMBL11953549 | 0.78 | ACHE (0.41) | WDR5DHODHCTSA | |
| SCHEMBL10302705 | 0.78 | GRM5 (0.37) | — | |
| SCHEMBL4402602 | 0.75 | CCR1 (0.54) | FEN1ALOX5APCYP11B1CYP11B2DHODH | |
| SCHEMBL19154379 | 0.75 | PTGS2 (0.45) | FEN1ALOX5APGRIN2B | |
| SCHEMBL13262957 | 0.73 | PTPRC (0.44) | DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8216489-B2 | Three-ring liquid crystal compound having lateral fluorine, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20110037024-A1 | THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110037024-A1 | THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, L3MBTL3 | CNR2 2145/4885WDR5 1067/4885FEN1 2927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.